Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)

被引：0
|
作者：
Hughes, Derralynn [1 ]
Wilcox, William [2 ]
Hopkin, Robert J. [3 ]
Ganesh, Jaya [4 ]
Bernat, John [5 ]
Goker-Alpan, Ozlem [6 ]
Nicholls, Kathy [7 ]
Deegan, Patrick [8 ]
Pahl, Madeleine [9 ]
Whitley, Chester B. [10 ]
Chen, Michael
Cao, Liching
Schreeb, Katharina H.
机构：
[1] Royal Free London Hosp, London, England
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[4] Icahn Sch Med Mt Sinai, New York, NY USA
[5] Univ Iowa, Iowa City, IA USA
[6] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA
[7] Addenbrookes Hosp, Cambridge, England
[8] Univ Calif Irvine, Irvine, CA USA
[9] Univ Minnesota, Minneapolis, MN USA
[10] Sangamo Therapeut Inc, Richmond, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2025年 / 144卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2024.108773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
    Hopkin, Robert J.
    Ganesh, Jaya
    Bernat, John
    Goker-Alpan, Ozlem
    Nicholls, Kathleen
    Pahl, Madeleine V.
    Deegan, Patrick B.
    Whitley, Chester B.
    Hughes, Derralynn
    Cao, Liching
    Chen, Michael
    Shiue, Lisa
    Rojkjaer, Lisa
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [2] STAAR, a phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Dose escalation phase results
    Hopkin, Robert J.
    Ganesh, Jaya
    Deegan, Patrick
    Goker-Alpan, Ozlem
    Bernat, John
    Wilcox, William R.
    Pahl, Madeleine V.
    Whitley, Chester B.
    Hughes, Derralynn
    Nicholls, Kathleen
    Cao, Liching
    Chen, Michael
    Shiue, Lisa H.
    Bowden, Emma
    Jaggumantri, Sravan
    Passalacqua, Cristobal
    Souberbielle, Bernard
    Cockroft, Bettina M.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 61 - 62
  • [3] Preliminary results of STAAR, a Phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
    Deegan, P.
    Ganesh, J.
    Goker-Alpan, O.
    Hopkin, R.
    Bernat, J.
    Wilcox, W.
    Cao, L.
    Chen, M.
    Shiue, L.
    Bowden, E.
    Jaggumantri, S.
    Passalacqua, C.
    Souberbielle, B.
    Cockroft, B.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A9 - A10
  • [4] A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
    Meyer, Kathleen E.
    Lorget, Florence
    Prawdzik, Gregg
    Falaleeva, Marina
    Cao, Liching
    Falese, Lillian
    Huston, Marshall W.
    Hettini, Khaled
    Lu, Yanmei
    Ledeboer, Annemarie
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [5] Analysis of Gb3 inclusions in kidney biopsies as a biomarker supporting the ST-920 phase 1/2 clinical trial for Fabry disease
    Cheung, Ruby
    Cao, Liching
    Sinclair, Elena
    Meyer, Kathleen
    Lu, Yanmei
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [6] Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease
    Thomas, Mark
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S119 - S119
  • [7] Anti-AAV6 antibody assay for patient enrollment supporting ST920 phase 1/2 study for Fabry disease
    Cao, Liching
    Ledeboer, Annemarie
    Pan, Yonghua
    Lu, Yanmei
    Meyer, Kathleen
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [8] AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: interim results from Phase 1 and Phase 2 studies
    Thomas, M.
    Nicholls, K.
    Carnley, B.
    Trame, M. N.
    Mason, C.
    Huertas, P.
    Asatryan, A.
    Escolar, D. M.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A23 - A23
  • [9] Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study
    Shah, Ami J.
    Lopez Lorenzo, Jose Luis
    Sevilla, Julian
    Navarro, Susana
    Llanos, Lucia
    de Camino Gaisse, Begona Perez
    Sanchez, Sol
    Zubicaray, Josune
    Glader, Bert
    Chien, May
    Bustamante, Oscar Quintana
    Zeini, Miriam
    Choi, Grace
    Nicoletti, Eileen
    Rao, Gayatri R.
    Grazia Roncarolo, Maria
    Bueren, Juan A.
    Schwartz, Jonathan D.
    Segovia, Jose C.
    BLOOD, 2022, 140 : 4902 - 4903
  • [10] Hematopoietic Stem Cell Gene Therapy for Cystinosis: Updated Results from a Phase 1/2 Clinical Trial
    Cherqui, Stephanie
    MOLECULAR THERAPY, 2022, 30 (04) : 29 - 29
12345